The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

Since April, Grifols has been collecting blood plasma donated by healthy people who have recovered from COVID-19. The company processes plasma, collected at its 300-plus donation centers, to yield ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

(Guy Leblanc/Radio-Canada ) All three New Brunswick clinics are owned by Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, formerly known as Canadian Plasma Resources.

It can be transfused directly into patients in urgent situations, such as severe infection and excessive bleeding, or it can be manufactured into medications like immunoglobulins, which is what is ...

"Grifols developed its new fibrinogen to be more convenient, faster to prepare and storable at room temperature, an advantage over alternatives such as cryoprecipitate or fresh frozen plasma when ...

All three New Brunswick clinics are owned by Grifols, a Spanish multinational pharmaceutical and chemical manufacturer, formerly known as Canadian Plasma Resources. There are now 13 sites spread ...